A 24 Week Randomized, Double-blind, Placebo-controlled Withdrawal Trial With a 16 Week Open-label lead-in Phase, and 64 Week Open-label Follow-up, to Evaluate the Effect on Clinical Response and the Safety of Tocilizumab in Patients With Active Polyarticular-course Juvenile Idiopathic Arthritis

Trial Profile

A 24 Week Randomized, Double-blind, Placebo-controlled Withdrawal Trial With a 16 Week Open-label lead-in Phase, and 64 Week Open-label Follow-up, to Evaluate the Effect on Clinical Response and the Safety of Tocilizumab in Patients With Active Polyarticular-course Juvenile Idiopathic Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2018

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms CHERISH
  • Sponsors Roche
  • Most Recent Events

    • 01 Jul 2018 Results (n=187) of post-hoc analysis assessing growth rates in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with Tocilizumab in this 2-year CHERISH trial, published in The Journal of Rheumatology.
    • 10 Jun 2017 Biomarkers information updated
    • 16 May 2014 Results published in the Annals of the Rheumatic Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top